MYGN Myriad Genetics Inc.

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Management will also participate in four upcoming investor healthcare conferences

SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes.

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter 2024.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call.

Q2 Investor Conferences

Management will also be participating in the following investor conferences:

  • The Bank of America Securities Health Care Conference with a presentation from Sam Raha, chief operating officer, and Scott Leffler, chief financial officer, on Tuesday, May 14, 2024 at 8:15pm ET.
  • The Piper Sandler Virtual Cancer Testing Day with a presentation from Dale Muzzey, chief scientific officer, on May 21, 2024 at 11am ET.
  • The Leerlink Partners Healthcare Crossroads Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on May 30, 2024 at 11am ET.
  • The 45th Annual Global Goldman Sachs Global Healthcare Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on June 12, 2024 at 3:20pm ET.

Live and archived webcasts of all presentations can be viewed at .

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

Investor Contact

Matt Scalo

(801) 584-3532

Media Contact

Glenn Farrell

(385) 318-3718



EN
30/04/2024

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE
Free
MYGN Myriad Genetics...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...

3h / 28m 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Re...

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, H...

20h / 23m 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

FirstGene Study Demonstrates High Analytical Sensitivity and Specifici...

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the in Clinical Chemistry. The showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene condit...

February 19, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial...

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of ...

February 16, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study...

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch Precise MRD with select...

January 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch